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Imaging Inﬂammation in Atherosclerosis
Another Step Forward*
Prediman K. Shah, MD
Los Angeles, CaliforniaAtherosclerosis is an immuno-inflammatory disease of
the arterial wall involving multiple intertwined biolog-
ical processes. These processes include nonlaminar
flow that creates a pro-inflammatory endothelial phe-
notype and helps localize atherosclerotic lesions pref-
erentially to regions of disturbed flow; atherogenic
lipoprotein entry into the arterial wall leading to their
retention and oxidation; inflammatory gene induction
with endothelial activation leading to recruitment of
mononuclear cells followed by their retention and
activation; conversion of monocytes into macrophages
and foam cells after ingestion of lipids; smooth muscle
cell migration and proliferation; extracellular matrix
See page 1213
remodeling; cell death; and angiogenesis (1,2). Ath-
erosclerosis takes its greatest toll by triggering
thrombosis usually superimposed on a ruptured
fibrous cap; however, as many as 30% of thrombi
superimposed on plaques might occur in absence of
plaque rupture with only superficial endothelial
erosions (1–3). Nearly one-half of all potentially
lethal acute thrombotic manifestations of athero-
sclerosis, such as acute myocardial infarction or
sudden cardiac death, occur in individuals without
prior warning symptoms or knowledge of disease.
Although atherosclerosis is a multifocal disease,
certain types of plaques, so-called high-risk plaques
or vulnerable plaques, are more likely to be associ-
ated with thrombosis (1–3). Rupture-prone plaques
are characterized by a large lipid-rich core, thinned
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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sion of Cardiology and the Cedars Sinai Heart Institute, Cedars Sinai
Medical Center, Los Angeles, California.out collagen and smooth muscle cell depleted fi-
brous cap, outward remodeling, increased plaque
neo-angiogenesis, and increased inflammatory cell
infiltration in the fibrous cap and adventitia (2,3).
Noninvasive detection of subclinical atherosclerosis
in various arterial beds is now possible with ultra-
sound, computed tomography (CT), and cardiac
magnetic resonance imaging; however, identifica-
tion of plaques that are at high risk for triggering
thrombosis in the near-term remains a challenge.
Inflammation in atherosclerosis is linked to several
biological processes, such as foam cell formation,
extracellular matrix degradation and arterial wall
remodeling, cell death, plaque neoangiogenesis and
intraplaque hemorrhage, plaque progression, lipid
core expansion, plaque rupture, and thrombosis
(1–3). Noninvasive imaging of molecules and path-
ways or biological processes linked to inflammation
holds promise for identification of high-risk plaques
and monitoring the effects of therapeutic interven-
tions (4–7). A number of modalities to image
inflammation in the arterial wall are in various
stages of preclinical and clinical development (4–
6). Positron emission tomography (PET) imaging
with 18F-labeled deoxyglucose (18FDG ) as a met-
abolic tracer is one of these techniques (4,5). The
18FDG is widely used clinically for cancer imaging,
and recent studies have shown that it also accumu-
lates in the atherosclerotic lesion, presumably indi-
cating enhanced glucose uptake by metabolically
active macrophages and possibly other cells (7–9).
Despite promising initial clinical results with
18FDG PET imaging in detecting inflammation in
human carotid plaques, the possibility that meta-
bolically active cells other than inflammatory cells
could also take up 18FDG could reduce the speci-
ficity of this approach. Furthermore, the increased
background glucose uptake in metabolically active
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1224yocardium makes imaging of inflammation in
uman coronary plaques more challenging.
In this issue of iJACC, Nahrendorf et al. (10)
resent their pre-clinical data on imaging vascular cell
dhesion molecule (VCAM)-1 by hybrid imaging
nvolving PET as a molecular imaging tool and CT as
n anatomical imaging tool in murine atherosclerosis.
ecruitment of mononuclear inflammatory cells into
he arterial wall is initiated by an interaction between
key adhesion molecule of the immunoglobulin
uperfamily—VCAM-1—expressed on the activated
ndothelium and its ligand, very late antigen (VLA)-4
xpressed on the leukocyte surface (11). The expres-
ion of VCAM-1 is increased at lesion-prone sites and
n atherosclerotic plaques, where it is expressed by
ndothelial as well as smooth muscle cells and mac-
ophages (12). In an attempt to image VCAM-1
xpression in the atherosclerotic lesions, the authors
rst identified a linear synthetic peptide VHPKQHR
ith sequence homology to VLA-4, with in vivo
hage display with 3 rounds of positive iterative
election from aortas of apolipoprotein E (ApoE)/
ice (10). The increased affinity of VHPKQHR to
CAM-1 was attributed to the multivalent tetrameric
ature of the peptide (4V), and its binding to
CAM-1 was shown to be highly specific (10). The
V was then labeled with 18F (18F-4V) for PET
maging. In addition, the authors also used a fluores-
ent version of the 18F-4V to allow for rapid identi-
cation of the peptide in tissues. Imaging was per-
ormed in 3 different settings where VCAM-1 is
pregulated: the setting of aortic atherosclerosis in old
ypercholesterolemic ApoE/ mice fed a high fat
iet, in a murine model of acute myocardial infarction,
nd in a murine model of cardiac transplant rejection
10). For atherosclerosis, PET imaging was used on
xcised murine aortas as well as in intact animals 1 to
h after injection of 18F-4V to localize in vivo
CAM-1 expression along with high-resolution con-
rast enhanced CT to provide anatomic reference to
he aortic root. Anatomic location of VCAM-1 ex-
ression was verified by immunohistological assess-
ent and with fluorescence microscopy after injection
f fluorescence labeled 18F-4V. Further validation of
n vivo VCAM-1 imaging results with PET was
chieved with comparison with quantitative polymer-
se chain reaction data for VCAM-1 and macrophage
arker CD68 expression in tissue. The authors show
hat 18F-4V accumulates in atherosclerotic plaques,
ostly in the endothelium overlying aortic plaques,
nd is detected by in vivo and ex vivo PET/CT
maging, and the tracer accumulation correlates rea-
onably well with polymerase chain reaction evidence hor VCAM-1 (R  0.79) and CD68 (R  0.5)
xpression (10). Furthermore, pre-injection of a spe-
ific anti–VCAM-1 monoclonal antibody into the
ice markedly reduced 18F-4V uptakes, indicating
igh level of VCAM-1 specificity of the tracer. The
uthors also show increased uptake of 18F-4V in
yocardium after myocardial infarction and during
ransplant rejection.
This is an important advance in molecular imaging
f vascular inflammation that brings us a step closer to
ealizing this possibility in humans. The authors
rovide compelling data to support a reasonably good
ensitivity and specificity of their PET tracer and
maging techniques for identifying VCAM-1 as a
arker of vascular inflammation. The biodistribution
inetics with a large ratio of uptake in atherosclerotic
ersus nonatherosclerotic aorta as well as a short
irculating half life make the tracer quite attractive for
otential human imaging. The authors also show that
torvastatin treatment in the mouse reduced 18F-4V
ptake consistent with its known anti-inflammatory
ffects, thus suggesting the possibility that this imag-
ng method might have a dynamic range to allow
ssessment of serial changes and effects of therapeutic
nterventions on plaque inflammation. That would be
et another step in the right direction.
However, several caveats should serve as a reminder
f challenges ahead in translating this work to the
tudy of human atherosclerosis. First, we must ac-
nowledge that the authors did not directly image
nflammation but imaged a key molecule that is
mportant in leukocyte-endothelial adhesion, which is
n early step in arterial wall leukocyte recruitment.
hus, it is plausible that plaque inflammation could be
ltered at steps downstream from the initial step of
dhesion by interventions that affect leukocyte chemo-
axis, activation, survival, or egress from the lesion,
hich could modulate inflammation in the plaque
ithout a change in VCAM-1 expression. Dansky et
l. (13) have shown that, in a murine model, elevated
po A-I and high-density lipoprotein cholesterol
evels inhibit foam cell formation at a stage after
ubendothelial lipid retention, endothelial VCAM-1
nduction, and monocyte adherence. Similarly, an
thero-regressive environment was associated with
gress of macrophages from the atherosclerotic lesion
ithout affecting the entry of monocytes, leading to a
et decrease in plaque inflammation; VCAM-1 im-
ging in this setting might be unable to detect this
henomenon (14). Second, leukocyte recruitment into
he atherosclerotic lesion might also occur through
laque and adventitial neovasculature, and it is unclear
ow the current methodology would work in that
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1225etting (15). These caveats are reinforced by the
uthor’s data, which show that the 18F-4V uptake in
he aortic lesions correlated better with VCAM-1
ene expression (R  0.79) than with macrophage
arker CD68 gene expression (R  0.5). It would
ave been interesting to know the correlation between
he extent of plaque macrophage immunoreactivity (a
ore direct index of plaque inflammation) and the
agnitude of 18F-4V uptake; unfortunately, these
ata are not provided. Another potential limitation of
he imaging modality used by the authors is the
merging evidence of heterogeneity of monocytes and
acrophages in mice and humans, where different
ubsets might have pro-inflammatory or possibly anti-
nflammatory pro-healing effects that could not be
istinguished on the basis of VCAM-1 imaging (16).
lthough the approach used by authors seems to have
orked reasonably well in the murine aortic root
therosclerosis model, it remains to be seen whether it
ould be equally good for imaging other relevant
ascular sites, such as the coronary arteries and the
arotid arteries. Finally, although in humans inflamed
ipid-rich plaques are prone to rupture and thrombo-
is, nearly one-third of coronary thrombi evolve from
laques that do not have a large lipid core or signifi-
ant inflammation but have superficial endothelialJ Am Coll Cardiol 2009;53:2039–50. formation in Apolaques would be definitively identified with
CAM-1 imaging (3).
Notwithstanding these potential limitations, the
olecular imaging approach developed by the authors
s definitely a step forward in our quest for imaging at
east an important subset of high-risk plaques. It will
lso be of great interest to learn how the approach
sed by Nahrendorf et al. (10) will compare with
lternative imaging modalities already under clinical
nvestigation for structural and functional imaging of
uman atherosclerosis, such as aortic and carotid
agnetic resonance; contrast enhanced CT coronary
ngiography; and 18FDG PET imaging of inflamma-
ion in aorta, carotid arteries, and coronary arteries (in
ombination with CT) (4–9,16,17).
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